By Fineline Cube 
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue of ¥586 million, a 73 % year‑on‑year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).
Financial Highlights
| Metric | Q3 2025 | YoY Change |
|---|---|---|
| Operating Revenue | ¥586 million | +73 % |
| Core‑Product Sales (Sunvozertinib + Golidocitinib) | 70 % of total | +85 % |
| R&D Expenditure | ¥42 million | +15 % |
- NRDL Impact – The NRDL listing has accelerated volume growth, driving both market share and top‑line revenue.
- Stable Cash Flow – Despite increased R&D outlays, operating cash flow remains positive, supporting future pipeline investments.
Pipeline & R&D Progress
- Birelentinib (DZD8586) – A global first‑in‑class LYN/BTK dual‑target inhibitor, has entered Phase III trials worldwide and received Fast‑Track Designation from the U.S. FDA.
- DZD6008 – A fourth‑generation EGFR TKI, is progressing its dose‑expansion study in EGFR‑mutated non‑small‑cell lung cancer (NSCLC).
- Seven Global Pipelines – Dizal maintains full global rights to seven small‑molecule candidates, each with First‑in‑Class (FIC) or Best‑in‑Class (BIC) potential.
Strategic Outlook
- NRDL Momentum – Continued inclusion of Sunvozertinib and Golidocitinib is expected to sustain revenue growth through 2026.
- R&D Pipeline – Successful Phase III data for Birelentinib and dose‑expansion milestones for DZD6008 will expand the company’s therapeutic footprint.
- Global Expansion – Full ownership of pipeline assets positions Dizal for strategic license or partnership deals in key international markets.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech